Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 95%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
41,339
Total Claims
$3.8M
Drug Cost
1,350
Beneficiaries
$2,784
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+164%
Opioid rate vs peers
5.9% vs 2.2% avg
+97%
Cost per patient vs peers
$2,784 vs $1,411 avg
+48%
Brand preference vs peers
15.7% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
5.9%
Opioid Rate
2,444
Opioid Claims
$59K
Opioid Cost
7.0%
Long-Acting Rate
Brand vs Generic
Brand: 6,472 claims · $2.9M
Generic: 34,703 claims · $880K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,084 | $398K |
| Semaglutide | 253 | $291K |
| Encorafenib | 11 | $177K |
| Dulaglutide | 275 | $171K |
| Deutetrabenazine | 43 | $128K |
| Rivaroxaban | 345 | $120K |
| Empagliflozin | 167 | $72K |
| Pimavanserin Tartrate | 26 | $60K |
| Budesonide/Formoterol Fumarate | 126 | $54K |
| Linagliptin | 164 | $50K |
| Insulin Glargine,hum.Rec.Anlog | 189 | $44K |
| Insulin Glargine,hum.Rec.Anlog | 129 | $40K |
| Sitagliptin Phosphate | 61 | $40K |
| Linaclotide | 54 | $36K |
| Tirzepatide | 37 | $36K |
Prescribing Profile
Patient Profile
74
Avg Age
58%
Female
2.36
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data